As­traZeneca inks $8.4B pact with Mer­ck as cru­cial MYS­TIC study fails and shares plunge

As­traZeneca’s cru­cial com­bi­na­tion tri­al of dur­val­um­ab (Imfinzi) and treme­li­mum­ab has failed the pri­ma­ry end­point on pro­gres­sion-free sur­vival as a first-line ther­a­py for non-small cell lung can­cer. The shock waves from that news im­me­di­ate­ly ripped through its share price, eras­ing bil­lions in mar­ket val­ue and spurring some fevered spec­u­la­tion about the phar­ma gi­ant’s fu­ture. And with­in hours an­a­lysts start­ed to raise the prospect that the fall­out just might be bad enough to in­spire a new megamerg­er takeover at­tempt.

The news marks a ma­jor set­back for As­traZeneca $AZN. An­a­lysts have been wait­ing months for the re­sults, see­ing it as a crit­i­cal test of CEO Pas­cal So­ri­ot’s plan to turn things around at the phar­ma gi­ant af­ter five years at the helm. A suc­cess here could have vault­ed As­traZeneca in­to the front ranks of a fu­ri­ous as­sault on a multi­bil­lion-dol­lar mar­ket; fail­ure was deemed a dis­as­ter. The com­bo study of the PD-L1 and CT­LA-4 check­point drugs is con­sid­ered the most im­por­tant tri­al that the phar­ma gi­ant has been pur­su­ing, and its biggest stock cat­a­lyst of the year.

Sean Bo­hen, As­traZeneca

As­traZeneca’s shares cratered on the news, plung­ing 15% and wip­ing out more than $12 bil­lion in mar­ket cap. Mer­ck shares $MRK, mean­while, surged 4% in pre-mar­ket trad­ing as the prospect of a di­rect threat to its lead po­si­tion on lung can­cer re­ced­ed. And once again Bris­tol-My­ers Squibb was dam­aged, drop­ping 6% as in­vestors con­sid­ered the con­se­quences of fail­ure for a PD-(L)1 and CT­LA-4 sim­i­lar to its own matchup for Op­di­vo and Yer­voy in the CM-227 tri­al.

As­traZeneca sought to take the sting out of the tri­al fail­ure by si­mul­ta­ne­ous­ly an­nounc­ing a ma­jor new de­vel­op­ment and com­mer­cial­iza­tion part­ner­ship with Mer­ck for its promis­ing PARP Lyn­parza along with the ex­per­i­men­tal MEK drug selume­tinib.

Mer­ck $MRK agreed to pay a whop­ping $2.35 bil­lion in an up­front and op­tion fee to co-de­vel­op and mar­ket the two drugs, work­ing on monother­a­py stud­ies as well as com­bi­na­tions along­side their ri­val PD-(L)1 drugs Imfinzi and Keytru­da. Mer­ck will al­so pay up to $6.15 bil­lion in mile­stones, mak­ing this an $8.4 bil­lion deal — one of the largest of its kind.

But it wasn’t enough to soft­en the blow.

As­traZeneca first ac­knowl­edged the fail­ure of MYS­TIC in a down­load ear­ly Thurs­day of new clin­i­cal tri­al re­sults, then con­firmed it in a re­lease. There was more bad news.

“As a sec­ondary end­point, al­though not for­mal­ly test­ed,” the com­pa­ny adds, “Imfinzi monother­a­py would not have met a pre-spec­i­fied thresh­old of PFS ben­e­fit over SoC in this dis­ease set­ting.”

“We now have to wait for over­all sur­vival da­ta in the first half of 2018,” said So­ri­ot in a call with re­porters, adding that he was dis­ap­point­ed by the ini­tial re­sults. “This is the main end­point,” he added about OS, look­ing to keep hope alive.

As­traZeneca was 5th to mar­ket with a PD-(L)1 drug. Mer­ck and Bris­tol-My­ers Squibb were able to seize the lead in the megablock­buster can­cer mar­ket, so As­traZeneca re­cal­i­brat­ed its de­vel­op­ment plans to em­pha­size its com­bi­na­tion strat­e­gy.

So­ri­ot has re­peat­ed­ly flashed signs of the stress that has been build­ing over MYS­TIC. It’s ex­tra­or­di­nary for any Big Phar­ma to be in a po­si­tion like this, where one tri­al can play such a cru­cial role in de­ter­min­ing a com­pa­ny’s fate.

This morn­ing, though, So­ri­ot and R&D chief Sean Bo­hen de­fend­ed their de­sign of the MYS­TIC study, putting PFS in for the first take.

“If it had been suc­cess­ful every­one would have been thrilled,” Bo­hen said about MYS­TIC PFS da­ta. So­ri­ot al­so bat­ted back con­cerns about the po­ten­tial neg­a­tive im­pact of crossovers on the OS end­point, which sev­er­al an­a­lysts have raised as a po­ten­tial hur­dle on sur­vival rates.

“Peo­ple are com­ment­ing on the dan­ger of crossover,” the CEO told re­porters. “We have lim­it­ed crossover. The risk there is much low­er than in oth­er stud­ies.”

We may nev­er know, though, what role the da­ta played in the strange sto­ry about Te­va’s re­port­ed move to of­fer the CEO’s job to So­ri­ot. Over sev­er­al days As­traZeneca’s stock shed bil­lions in mar­ket cap as ru­mors float­ed about his pos­si­ble de­par­ture from As­traZeneca. So­ri­ot dis­pelled those ru­mors with an in­ter­nal memo un­der­scor­ing his in­ten­tion to stay and fight it out. Back when Pfiz­er was look­ing to buy the com­pa­ny, he pledged As­traZeneca will al­most dou­ble last year’s $23 bil­lion in rev­enue by 2023.

That goal, how­ev­er, looks like it’s re­ced­ing — at least to­day. In H1 As­traZeneca’s to­tal rev­enue de­clined 11% com­pared to the same pe­ri­od in 2016 as fran­chise rev­enue con­tin­ued to erode in the face of gener­ic com­pe­ti­tion. The com­pa­ny ex­pects a sin­gle-dig­it de­cline for the year in what has been pre­sent­ed as the bot­tom point for the num­bers.

So­ri­ot re­peat­ed­ly re­fused to di­rect­ly ad­dress the Te­va sto­ry to­day, but he pub­licly re­it­er­at­ed his in­ten­tion to stay fo­cused on his goals at the phar­ma gi­ant.

“I’m com­mit­ted to de­liv­er­ing on our strat­e­gy to re­turn­ing to growth,” he said. Not every­thing has worked out, he not­ed, but So­ri­ot in­sist­ed that the com­pa­ny had made “enor­mous progress.”

Pressed on Te­va, he added:

“I’m not a quit­ter. That is as far as I will go.”

Asked by Reuters’ Ben Hirschler about a share price that fell to £43 this morn­ing, com­pared to the £55 that Pfiz­er of­fered, the CEO said: “Over­all the pipeline is de­liv­er­ing…You have to give these things time,” says So­ri­ot. “There’s a lot more in our pipeline than MYS­TIC.”

As the dust set­tled lat­er in the day, new pre­dic­tions be­gan to cir­cu­late that the weak­ened share price could at­tract a new bid for the com­pa­ny. And As­traZeneca is in a much worse po­si­tion now to fight off an ac­qui­si­tion.


Im­age: Pas­cal So­ri­ot AP Im­ages

Dan Skovronsky, Eli Lilly CSO

UP­DAT­ED: An­a­lysts are quick to pan Eli Lil­ly's puz­zling first cut of pos­i­tive clin­i­cal da­ta for its Covid-19 an­ti­body

Eli Lilly spotlighted a success for one of 3 doses of their closely-watched Covid-19 antibody drug Wednesday morning. But analysts quickly highlighted some obvious anomalies that could come back to haunt the pharma giant as it looks for an emergency use authorization to launch marketing efforts.

The pharma giant reported that LY-CoV555, developed in collaboration with AbCellera, significantly reduced the rate of hospitalization among patients who were treated with the antibody. The drug arm of the study had a 1.7% hospitalization rate, compared to 6% in the control group, marking a 72% drop in risk.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED #ES­MO20: Trodelvy da­ta show that Gilead­'s $21B buy­out may have been worth the big pre­mi­um

Gilead CEO Dan O’Day has been on a shopping spree. And while some analysts gawked at the biotech’s recent $21 billion Immunomedics buyout, new data released at virtual ESMO 2020 suggest the acquisition may have been worth the hefty price.

The deal, announced last weekend, will give California-based Gilead $GILD Trodelvy, which was recently approved for metastatic triple-negative breast cancer (mTNBC).

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

#ES­MO20: As­traZeneca bur­nish­es Tagris­so's ad­ju­vant NSCLC pro­file with 'un­prece­dent­ed' re­duc­tion in brain mets. Can they win over skep­tics?

When AstraZeneca trumpeted “momentous” and “transformative” results for Tagrisso earlier this year at ASCO, some practitioners threw cold water on the ADAURA fervor. Sure, the disease-free survival data look good, but overall survival is the endpoint that matters when it comes to choosing adjuvant therapy for non-small cell lung cancer patients, the experts said.

The OS data still aren’t here, but AstraZeneca is back at ESMO to bolster their case with a look at brain metastasis data.

Exelixis CEO Michael Morrissey (file photo)

#ES­MO20: Look out Mer­ck. Bris­tol My­ers and Ex­elix­is stake out their com­bo’s claim to best-in-class sta­tus for front­line kid­ney can­cer

Now that the PD-(L)1 checkpoints are deeply entrenched in the oncology market, it’s time to welcome a wave of combination therapies — beyond chemo — looking to extend their benefit to larger numbers of patients. Bristol Myers Squibb ($BMY} and Exelixis {EXEL} are close to the front of that line.

Today at ESMO the collaborators pulled the curtain back on some stellar data for their combination of Opdivo (the PD-1) and Cabometyx (the TKI), marking a significant advance for the blockbuster Bristol Myers franchise while offering a big leg up for the team at Exelixis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Donald Trump and White House chief of staff Mark Meadows, before boarding Marine One (Getty Images)

Pric­ing deal col­laps­es over Big Phar­ma's re­fusal to is­sue $100 'cash card­s' be­fore the elec­tion — re­port

Late in August, as negotiations on a pricing deal with President Trump reached a boiling point, PhRMA president Stephen Ubl sent an email update to the 34 biopharma chiefs that sit on his board. He wrote that if the industry did not agree to pay for a $100 “cash card” sent to seniors before November, White House chief of staff Mark Meadows was going to tell the news media Big Pharma was refusing to “share the savings” with the elderly — and that all of the blame for failed drug pricing negotiations would lie squarely on the industry.

#ES­MO20: Alk­er­mes of­fers their first snap­shot of a ben­e­fit for their next-gen IL-2 drug. But why did 1 pa­tient starve to death?

Everyone in the cancer R&D arena is looking to build new franchises around better drugs and combos. And one busy pocket of that space is centered entirely on creating an IL-2 drug that can be as effective as the original without the toxicity that damned it to the sidelines.

Alkermes $ALKS formally tossed its hat into the ring of contenders at virtual ESMO today, highlighting the first glimpse of efficacy for their candidate, ALKS 4230, as both a monotherapy as well as in combination with Merck’s Keytruda.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Albert Bourla (Photo by Steven Ferdman/Getty Images)

Pfiz­er match­es Mod­er­na with their full Covid-19 tri­al blue­print — As­traZeneca says it will un­veil its pro­to­col 'short­ly'

Yesterday, after sustained public pressure as Moderna released its Phase III Covid-19 trial blueprint, Pfizer released its own full trial design for their vaccine trials. The move was designed to boost transparency and shore up public trust in the vaccines, but it also revealed differences in how the two companies are approaching the much-watched studies while failing to satisfy the demands of the fiercest advocates for transparency.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

#ES­MO20: Re­gen­eron, Sanofi eye an­oth­er first for their PD-1 con­tender Lib­tayo with promis­ing da­ta for on­col­o­gy niche

Regeneron and Sanofi took another step forward in the long march towards a greatly expanded market for their late-bloomer PD-1 checkpoint Libtayo.

The two occasional allies posted an objective response rate of 31% for Libtayo among 84 patients suffering from advanced cases of basal cell carcinoma at virtual ESMO. That spotlights progress for 26 patients, 5 of whom had a complete response. The data also reflect a boost in the number of responses seen from the last cut of the numbers.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Albert Bourla, Pfizer CEO (Steven Ferdman/Getty Images)

Pfiz­er ex­ecs con­fi­dent­ly tap their top 10 block­busters-to-be. But what are the chances of sur­viv­ing PhI­II, let alone hit­ting these big peak sales es­ti­mates?

Pfizer’s top executive team doesn’t lack for confidence.

Where many Big Pharmas would be reluctant to put a peak sales figure on their late-stage drugs, Pfizer CEO Albert Bourla has shrugged off the usual diffidence to outline where the pharma giant expects to get $15 billion-plus.

The list, outlined this week during their investor presentations, is topped by 3 drugs in the $3 billion-plus peak sales category. They are:

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.